Abstract:Qi Wang, 1– 3, &ast Jiaxin Dong, 4, &ast Mengxian Du, 1, 3, &ast Xinna Liu, 1– 3 Shiqi Zhang, 1 Di Zhang, 1, 3 Wanyun Qin, 1, 3 Xikun Xu, 1, 2 Xianghui Li, 1, 3 Ruidong Su, 1, 2 Leyi Qiu, 1, 2 Baoqiang Li, 4, 5 Huiping Yuan 1 1 Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China; 2 The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Harbin, People's Republic of China; 3 Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China; 4 Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin, People's Republic of China; 5 Laboratory of Dynamics and Extreme Characteristics of Promising Nanostructured Materials, Saint Petersburg State University, St. Petersburg, Russia &astThese authors contributed equally to this work Correspondence: Huiping Yuan, Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, People's Republic of China, Email Baoqiang Li, Institute for Advanced Ceramics, State Key Laboratory of Urban Water Resource and Environment, Harbin Institute of Technology, Harbin, 150081, People's Republic of China, Email Introduction: Glaucoma is a prevalent cause of irreversible vision impairment, characterized by progressive retinal ganglion cells (RGCs) loss, with no currently available effective treatment. Rapamycin (RAPA), an autophagy inducer, has been reported to treat glaucoma in rodent models by promoting RGC survival, but its limited water solubility, systemic toxicity, and pre-treatment requirements hinder its potential clinical applications. Methods: Chitosan (CS)-RAPA carbon dot (CRCD) was synthesized via hydrothermal carbonization of CS and RAPA and characterized by transmission electron microscopy, Fourier transform infrared spectra, and proton nuclear magnetic resonance. In vitro assays on human umbilical cord vein endothelial and rat retinal cell line examined its biocompatibility and anti-oxidative capabilities, while lipopolysaccharide-stimulated murine microglia (BV2) assays measured its effects on microglial polarization. In vivo, using a mouse retinal ischemia/reperfusion (I/R) model by acute intraocular pressure elevation, the effects of CRCD on visual function, RGC apoptosis, oxidative stress, and M2 microglial polarization were examined. Results: CRCD exhibited good water solubility and anti-oxidative capabilities, in the form of free radical scavenging. In vitro, CRCD was bio-compatible and lowered oxidative stress, which was also found in vivo in the retinal I/R model. Additionally, both in vitro with lipopolysaccharide-stimulated BV2 cells and in vivo with the I/R model, CRCD was able to promote M2 microglial polarization by activating autophagy, which, in turn, down-regulated pro-inflammatory cytokines, such as IL-1β and TNF-α, as well as up-regulated anti-inflammatory cytokines, such as IL-4 and TGF-β. All these anti-oxidative and anti-inflammatory effects ultimately aided in preserving RGCs, and subsequently, improved visual function. Discussion: CRCD could serve as a potential novel treatment strategy for glaucoma, via incorporating RAPA into CDs, in turn not only mitigating its toxic side effects but also enhancing its therapeutic efficacy. Keywords: retina, ischemia/reperfusion injury, rapamycin, carbon dots, microglial polarization, autophagy Graphical Glaucoma, a neurodegenerative ocular disease, is characterized by selective, progressive, and irreversible retinal cell degeneration, particularly retinal ganglion cells (RGCs) and optic nerves, due to elevated intraocular pressure (IOP). 1,2 Retinal ischemia/reperfusion injury, caused by high IOP, is an important risk factor contributing to RGC death. Despite extensive efforts towards early diagnosis and IOP reduction, via either medical or surgical interventions, continued RGC degeneration still threatens patient visual health. 3,4 Owing to the fact that the mammalian retina lacks regenerative capacities, resulting in irreversible RGC loss, it is therefore imperative to develop alternative strategies to effectively achieve neuroprotection, as well as minimizing side effects, in order to enhance and complement current ophthalmic treatments. Along with mechanical pressure-induced injuries, IOP-induc -Abstract Truncated-

Rapamycin suppresses neuroinflammation and protects retinal ganglion cell loss after optic nerve crush

Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model

Rapamycin inhibited photoreceptor necroptosis and protected the retina by activation of autophagy in experimental retinal detachment.

Chitosan-Rapamycin Carbon Dots Alleviate Glaucomatous Retinal Injury by Inducing Autophagy to Promote M2 Microglial Polarization

Protection of Pattern Electroretinogram and Retinal Ganglion Cells by Oncostatin M after Optic Nerve Injury

Ripa-56 protects retinal ganglion cells in glutamate-induced retinal excitotoxic model of glaucoma

Rapamycin Alleviates Neuronal Injury and Modulates Microglial Activation After Cerebral Ischemia

Neuro-protection of Retinal Stem Cells Transplantation Combined with Copolymer-1 Immunization in a Rat Model of Glaucoma

Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma

RIP1 inhibition protects retinal ganglion cells in glaucoma models of ocular injury

Reversal of injury-associated retinal ganglion cell gene expression by a phosphodiesterase anchoring disruptor peptide

Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model

PACAP Attenuates Optic Nerve Crush-Induced Retinal Ganglion Cell Apoptosis Via Activation of the CREB-Bcl-2 Pathway

Protective effects of rapamycin on the retinal vascular bed during the vaso-obliteration phase in mouse oxygen-induced retinopathy model

Resveratrol protects retinal ganglion cells against ischemia induced damage by increasing Opa1 expression

Protective Effect of Rapamycin in Models of Retinal Degeneration.

Rac1 Conditional Deletion Attenuates Retinal Ganglion Cell Apoptosis by Accelerating Autophagic Flux in a Mouse Model of Chronic Ocular Hypertension.

Inhibition of Heat Shock Protein B8 Alleviates Retinal Dysfunction and Ganglion Cells Loss Via Autophagy Suppression in Mouse Axonal Damage

Microglial SIRT1 activation attenuates synapse loss in retinal inner plexiform layer via mTORC1 inhibition

RGC-specific ATF4 and/or CHOP deletion rescues glaucomatous neurodegeneration and visual function

Inhibition of CRMP2 Phosphorylation Suppresses Microglia Activation in the Retina and Optic Nerve and Promotes Optic Nerve Regeneration After Optic Nerve Injury